Immuneering (NASDAQ:IMRX) Director Acquires $101,082.15 in Stock

Immuneering Corporation (NASDAQ:IMRX) Director Thomas Schall bought 21,645 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was bought at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the purchase, the director owned 74,530 shares in the company, valued at approximately $348,055.10. This represents a 40.93% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Immuneering Price Performance

Shares of NASDAQ IMRX traded up $0.29 during mid-day trading on Tuesday, hitting $4.87. The company had a trading volume of 236,988 shares, compared to its average volume of 3,977,731. The firm’s 50 day simple moving average is $6.32 and its two-hundred day simple moving average is $5.82. The stock has a market cap of $314.71 million, a price-to-earnings ratio of -2.61 and a beta of 0.48. Immuneering Corporation has a 12 month low of $1.10 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Equities analysts forecast that Immuneering Corporation will post -1.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on IMRX. Oppenheimer upped their price objective on shares of Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Leerink Partners began coverage on Immuneering in a report on Friday, October 31st. They set an “outperform” rating and a $15.00 target price on the stock. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Immuneering in a research report on Tuesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Immuneering currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Hedge Funds Weigh In On Immuneering

Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Immuneering in the first quarter valued at about $32,000. China Universal Asset Management Co. Ltd. bought a new position in Immuneering in the third quarter valued at $35,000. Future Financial Wealth Managment LLC bought a new stake in Immuneering during the third quarter worth about $35,000. Kingsview Wealth Management LLC acquired a new stake in shares of Immuneering in the 2nd quarter valued at approximately $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Immuneering in the third quarter valued at $70,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.